期刊文献+

阿托伐他汀强化降脂治疗对不稳定型心绞痛患者血脂、血清血管性假血友病因子与血栓调节蛋白水平的影响 被引量:16

Influence of Intensive Lipid-lowering Therapy by Atorvastatin on Blood Lipid and Serum Von Willebrand Factor and Thrombomodulin Levels of Patients with Unstable Angina Pectoris
下载PDF
导出
摘要 目的:探讨阿托伐他汀强化降脂治疗对不稳定型心绞痛患者血脂、血清血管性假血友病因子(v WF)与血栓调节蛋白(TM)水平的影响。方法:不稳定型心绞痛患者88例随机分为强化组(n=44)和常规组(n=44)。两组均予以硝酸酯类、阿司匹林肠溶片、β-受体阻断药和低分子肝素等常规治疗。在此基础上,常规组加用阿托伐他汀片20 mg,po,qd,强化组加用阿托伐他汀片40 mg,po,qd。均连用8周。观察两组治疗前后血脂、血清v WF与TM水平变化,比较治疗期间两组心脏缺血相关事件发生率和药品不良反应。结果:治疗8周后,两组患者TC、TG和LDL-C水平均较前明显下降、HDL-C水平则明显上升(P<0.05),且强化组下降或上升幅度较对照组更明显(P>0.05);两组血清v WF与TM水平较前均有明显下降(P<0.05或0.01),且强化组下降幅度明显大于常规组(P<0.05)。强化组治疗期间心脏缺血相关事件发生率明显低于常规组(P<0.05)。两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿托伐他汀强化降脂治疗不稳定型心绞痛具有较好的疗效和安全性,能降低心脏缺血相关事件发生率,作用与其降低血脂及血清v WF与TM水平,改善血管内皮细胞功能有关。 Objective:To discuss the influence of intensive lipid-lowering therapy by atorvastatin on blood lipid and serum von Wille-brand factor ( vWF) and thrombomodulin ( TM) levels of patients with unstable angina pectoris. Methods: Totally 88 cases of patients with unstable angina pectoris were selected and divided into the intensive group (n=44) and the routine group (n=44) at random. The patients in the two groups were given routine medical treatment, such as nitrates, bayaspirin,β-blocker, low molecular heparin and etc. The patients in the routine group were orally given atorvastatin 20mg, qd, while the patients in the intensive group were given atorvastatin 40mg, qd with the treatment course of 8 weeks. The changes in serum vWF and TM levels in the two groups before and after the medical treatment were observed, and the occurrence rates of cardiac ischemia related events and untoward effect during the medical treatment were compared as well. Results:After the 8-week medical treatment, the levels of TC, TG and LDL-C in the two groups were obviously declined and the levels of HDL-C were obviously increased than those before the treatment (P〈0. 05 or P〈0. 01), and the declining and increasing rates in the intensive group were much higher than those in the routine group (P〈0. 05). The serum vWF and TM levels in the two groups were obviously declined than those before the treatment (P〈0. 05 or P〈0. 01), and the declining rates in the intensive group were much higher than those in the routine group (P〈0. 05). The occurrence rates of cardiac ischemia related events in the inten-sive group during the medical treatment were much lower than those in the routine group (P〈0. 05). Respectively 4 and 6 cases of unto-ward effect appeared in the routine group and the intensive group during the medial treatment with light symptom, and the difference showed no obvious statistical significance (P〉0. 05). Conclusion:Atorvastatin intensive lipid-lowering has favorable cur
出处 《中国药师》 CAS 2015年第1期94-96,共3页 China Pharmacist
关键词 不稳定型心绞痛 强化降脂 血管性假血友病因子 血栓调节蛋白 Unstable angina pectoris Intensive lipid-lowering Von Willebrand factor Thrombomodulin
  • 相关文献

参考文献11

二级参考文献145

共引文献2288

同被引文献173

引证文献16

二级引证文献117

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部